To read the full story, subscribe or sign in.

Asceneuron raises $100M for OGA inhibitor work in Alzheimer’s

July 16, 2024

Asceneuron SA has raised $100 million in an oversubscribed series C to take its lead small molecule, ASN-51, into phase II, with aim of demonstrating it prevents the formation of tau tangles and slows the progression of Alzheimer’s disease.

BioWorld Financings Neurology/psychiatric Small molecule Series C Europe

Today's news in brief

BioWorld

BioWorld briefs for Nov. 17, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Nov. 17, 2025.

With transdiagnostic approach, smaller target groups aren’t inevitably smaller markets

BioWorld

Despite the formidable challenges for developing precision psychiatry, the approach is notching its first successes in the preclinical and even some clinical...

With transdiagnostic approach, smaller target groups aren’t inevitably smaller markets

BioWorld Science

Despite the formidable challenges for developing precision psychiatry, the approach is notching its first successes in the preclinical and even some clinical...

Illustration of magnifying glass inspecting brain

Anchoring, and bootstrapping, psychiatry into the precision medicine era

BioWorld

Psychiatry has struggled to enter the precision medicine era. But through a mix of innovations and bootstrapping, progress is coming to the field. Scientists are...